ArticleFrontiers in medicine2026
Prognostic analysis and development of a prognostic model for EML4-ALK-positive lung cancer patients treated with ALK-TKIs.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate prognostic factors and establish prognostic models for EML4-ALK-positive non-small cell lung cancer (NSCLC) patients receiving ALK tyrosine kinase inhibitors (TKIs) treatment. Methods: We retrospectively analyzed 114 ALK-positive NSCLC patients treated at our institution from January 2020 to January 2024. Clinical data, laboratory results, imaging findings, and follow-up records were collected. Progression-free survival (PFS) and overall survival (OS) served as primary endpoints. Statistical methods included Kaplan-Meier analysis, Cox regression modeling, and nomogram construction (70% training set, 30% validation cohort). Model performance was evaluated using Harrell's C-index, calibration curves, and time-dependent receiver operating characteristic (ROC) analysis. Results: The median PFS was 30.97 months (95% CI: 25.43-36.52), while median OS was not reached. Multivariate analysis identified four independent PFS predictors: brain metastasis (HR = 2.15, Conclusion: Our study established that brain metastasis status, tumor characteristics, and systemic inflammatory markers significantly impact clinical outcomes in ALK-positive NSCLC patients undergoing TKI therapy. The developed prognostic models show satisfactory prognostic performance and may assist in clinical decision-making and patient stratification. These findings warrant further validation in prospective, multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.